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Abstract
The bacterial Cytochrome P450 (CYP) BM3 (CYP102A1) is one of the most active CYP iso-
forms. BM3 mutants can serve as a model for human drug-metabolizing CYPs and/or as
biocatalyst for selective formation of drug metabolites. Hence, molecular and computational
biologists have in the last two decades shown strong interest in the discovery and design of
novel BM3 variants with optimized activity and selectivity for substrate conversion. This led
e.g. to the discovery of mutant M11 that is able to metabolize a variety of drugs and drug-like
compounds with relatively high activity. In order to further improve our understanding of
CYP binding and reactions, we performed a co-crystallization study of mutant M11 and
report here the three-dimensional structure M11 in complex with dithiothreitol (DTT) at a res-
olution of 2.16 Å. The structure shows that DTT can coordinate to the Fe atom in the heme
group. UV/Vis spectroscopy and molecular dynamics simulation studies underline this find-
ing and as first structure of the CYP BM3 mutant M11 in complex with a ligand, it offers a
basis for structure-based design of novel mutants.
Introduction
The CYP enzyme family comprises 57 human isoforms serving various purposes. The human
drug-metabolizing CYPs are promiscuous enzymes with broad substrate specificity transform-
ing a variety of compounds to more soluble compounds and, thereby, facilitating their excre-
tion from the human organism [1]. The human CYPs also comprise highly selective enzymes
involved in e.g. steroidogenesis [2]. Recently, these CYPs have been shown to be potential tar-
gets for treatment of various forms of cancer [3, 4]. The plant kingdom contains 127 CYP fam-
ilies typically with more than 250 CYPs in each, and each CYP usually being responsible for
the stereoselective synthesis of a single compound [5]. The bacterial CYPs are interesting as
targets for certain diseases (e.g. Mycobacterium tuberculosis) [6]. Furthermore, they can be tai-
lored to mimic human CYPs and often be expressed in higher yield than their human ana-
logues [7].
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CYP BM3 from Bacillus megaterium (CYP102A1) is characterized by high turnover, and by
mutation of the natural variant it has been transformed to a biotechnologically important
enzyme capable of regio- and/or stereoselective synthesis of a variety of organic compounds,
including human drug metabolites [8]. A considerable part of the work by Frances H. Arnold,
who was awarded the Nobel Prize 2018 in chemistry, has focused on directed evolution of the
CYP BM3 to perform specific chemical reactions [9]. Several CYP BM3 mutants have been
screened for their ability to metabolize drug compounds, see for example reference [10]. One
mutant, the M11 mutant with mutations R47L/E64G/F81I/F87V/E143G/L188Q/Y198C/
E267V/ H285Y/G415S has shown to be highly active and able to metabolize a diverse set of
drug compounds [10–13]. In biocatalyst design the M11 mutant has served as template of fur-
ther BM3 variants. For example, introduction of a single mutation in M11 can yield mutants
that are capable of selective hydroxylation of steroids [14] or production of a toxicologically
relevant metabolite of the antibiotic flucloxacillin [15]. Recently, we reported a crystal struc-
ture of this "humanized" mutant in the absence of any organic ligand in the active site (Fig 1)
[16].
To analyze the possible effect of ligand binding to the promiscuous BM3 M11 variant, we
present here the crystal structure of the M11 mutant of CYP BM3 in complex with dithiothrei-
tol (DTT, Fig 1). Our crystal structure shows that DTT binds in an orientation allowing a sul-
fur atom to come in proximity of the heme iron and it represents the first CYP BM3 mutant
M11 structure in complex with a ligand as well as the first CYP structure with a hexa-coordi-
nated Fe atom with a mercapto-containing ligand occupying the axial position. Furthermore,
we support our crystallographic study by UV/Vis spectroscopy, molecular dynamics (MD)
simulations and database searches.
Materials and methods
Expression and purification
The M11 heme domain construct was generated as described previously [16]. In short, a stop
codon was introduced after residue 473 by PCR using the following primers: FW 5’- cgcac
catgggatccATGACAATTAAAGAAATGCCTCAG-3’ and RV 5’-aaagaattcctacta
TTTGCGTACTTTTTTAGCAGACTG-3’. 1 ng of pBluescript II KS (+) plasmid encoding the
BM3 M11 gene was used as a template [17]. The PCR fragment was transferred to pET-28a(+)
using BamHI and EcoRI restriction sites. The P450 BM3 mutant was expressed in Escherichia
coli BL21 cells and purified using a His-tag affinity column as reported previously [18]. CYP
concentrations were determined using carbon monoxide (CO) difference spectrum assay as
previously described [19]. Samples showed near complete conversion to the P450 form, with
negligible formation of a 420-nm peak.
To obtain the desired purity for crystallization, the protein was loaded onto a Q-Sepharose
anion exchange column (16x10 cm, using the AKTA purifier) and eluted with a gradient of
0–500 mM KCl in 50 mM Tris, 1 mM EDTA, pH 7.2. Heme-domain containing fractions
were then loaded onto a hydroxyapatite column (Bioscale Mini Ceramic Hydroxyapatite Car-
dridge, using the AKTA purifier) and eluted in a linear gradient of 25–500 mM KPi, pH 7.0
(200 ml). Pure fractions were pooled and concentrated using a 10K vivaspin membrane and
the buffer was exchanged to 10 mM Tris pH 7.0 with 10% glycerol (glycerol was added for sta-
bility during storage at -20˚C). The protein sample was mixed with loading dye (25mM Tris-
HCl pH 6.8; 2% β-mercaptoethanol; 5% glycerol; 0.008% Bromophenol Blue; 0.8% SDS; 4 M
Urea) and analyzed on SDS-PAGE. Furthermore, the sample was heated for 10 minutes at
80˚C instead of 5 minutes at 95˚C. Afterwards, one band of pure M11 heme construct was
clearly seen. Purity of the samples was determined to be>95% using SDS-PAGE.
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Crystallization of the CYP BM3 M11 heme domain in complex with DTT
Mefenamic acid was added as solid compound to the concentrated M11 protein sample (26.2
mg/ml in 10 mM Tris-HCl buffer pH 7 with 10% glycerol) and left to equilibrate for 48 hours.
Prior to the crystallization setup, DTT was added to the M11 protein sample with mefenamic
acid to a final concentration of 3 mM DTT. Crystals were grown using hanging drops mixing
1 μL of protein-ligand solution with 1 μL of the reservoir solution containing 18% PEG 4000,
0.1 M Tris pH 8.0, 0.25 M MgCl2, and 10 mM DTT at temperature 6˚C. Crystals grew within
one month. The crystals were cryo-protected using reservoir solution containing 10% PEG
400 before flash-cooling in liquid nitrogen.
Data collection, structure solution and refinement
Data collection was performed at Maxlab I911-3 [20]. The crystals belonged to space group C2
with four molecules in the asymmetric unit. The diffraction data were processed with XDS
[21] and scaled using SCALA [22] in the CCP4 program suite [23]. The structure was solved
by molecular replacement using PHASER [24] in CCP4 and with the structure of Cytochrome
P450 BM3 (PDB ID 3DGI, mol A) [25] as the search model. The PHENIX auto-building pro-
cedure [26] was used to aid construction of the initial model of the M11 mutant-ligand com-
plex. More than two third of the residues were rebuilt by the automatic procedure and most of
the remaining residues were added manually using COOT [27]. Some loop regions in chains C
and D could not be modelled due to missing electron density, as well as most of the residues of
the N-terminal tags and the last approximately 15 residues of the C-terms. Residues included
close to the terminals and close to the missing loops were modelled even though the electron
density is weak. The structure revealed electron density close to the heme group corresponding
to DTT. The final model was refined in Phenix with individual isotropic B values, TLS and
Fig 1. Structure of M11. (A) Three-dimensional structure of the heme domain of the CYP BM3 M11 mutant (without organic ligand in the active site; PDB
entry 5E9Z) [16]. (B) Zoom-in on active site showing a water molecule and Cys400 adopting the axial positions at the hexa-coordinated Fe atom in the heme
group. The 2D structure of DTT is also depicted.
https://doi.org/10.1371/journal.pone.0217292.g001
Structure of P450 BM3 mutant M11 bound to dithiothreitol
PLOS ONE | https://doi.org/10.1371/journal.pone.0217292 May 24, 2019 3 / 15
riding hydrogen atoms. MolProbity [28] was used to validate the model. Refinement statistics
are summarized in Table 1. The structure coordinates and corresponding structure factor file
of CYP BM3 M11 mutant in complex with DTT has been deposited in the Protein Data Bank
under the accession code 6IAO.
Binding studies
To determine dissociation constants of binding of DTT to CYP BM3 M11, binding spectra of
the substrate-protein complexes were aerobically acquired as published by Venkataraman
et al. [17]. DTT was dissolved in 100 mM KPi pH 7.4 and titrated in steps of 6 μM into a
cuvette containing 1 mL of 100 mM KPi pH 7.4 and 1 μM BM3 M11 domain, up to a final
additional volume of not more than 2% of the initial solution volume. UV/Vis difference spec-
tra were obtained on a Perkin Elmer Lambda 40 spectrophotometer at room temperature. The
substrate-free sample was subtracted from all acquired spectra. The difference in absorbance
between 380 nm and 420 nm was plotted and analyzed by nonlinear regression, by fitting the
data to the ‘one site—specific binding with hill slope’ function of GraphPad Prism 5.00
(Graphpad Software, San Diego, CA, USA) in order to obtain reported KD values.
Table 1. Crystal data, data collection and structure refinement of CYP BM3 M11 mutant in complex with DTT.
Data collection
Wavelength (Å) 1.0000
Space group C2
Cell dimensions
a, b, c (Å) 377.9, 59.9, 95.5
α, β, γ (deg.) 90.0, 95.7, 90.0
No. in asymmetric unit 4
Resolution (Å) 47.9–2.16 (2.28–2.16)
No. unique reflections 114,389 (16,259)
Rmerge (%) 13.9 (72.7)
I/ σI 4.2 (0.9)
Completeness (%) 99.6 (97.6)
Redundancy 5.1 (3.9)
CC1/2 0.99 (0.63)
Refinement
Rwork / Rfree (%) 15.9/20.2
No. residues
Protein 1807
HEM/DTT/PEG/GOL/Cl 4/5/2/4/20
Water 1256
B-factors (Å2)
Protein 26.7
HEM/DTT/PEG/GOL/Cl 14.8/54.8/72.4/56.5/40.9
Water 27.1
R.m.s. deviations
Bond lengths (Å) 0.005
Bond angles (deg.) 0.71
Non-glycine residues in allowed regions
of the Ramachandran plot (%)
99.9
https://doi.org/10.1371/journal.pone.0217292.t001
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Computational details
The Protein Preparation Wizard in Maestro Software version 11.1 was used to prepare the pro-
tein structures [29]. Bond orders were assigned, hydrogens added and all water molecules
removed. The hydrogen bonding network was optimized at pH 7.0. A restrained protein mini-
mization was performed using the OPLS-2005 force field [30] with convergence of heavy atom
positions to a root-mean-square deviation of 0.30 Å. Preparation of ligands was performed
with LigPrep in Maestro [29]. Possible tautomers and protonation states were generated at pH
7.0 ± 2.0. Coordinates, atom types and partial atomic charges of the heme group and the neu-
tral and mono-anionic forms of DTT are available in the S3 File. Docking was performed with
GOLD (Genetic Optimisation for Ligand Docking) program version 5.6 [31]. Proteins pre-
pared by Protein Preparation Wizard were used without additional modifications in GOLD.
The binding site was defined to be within 15 Å around the heme Fe atom (using a value of 10
or 20 Å did not affect the conclusions from our docking study). Ligands prepared by LigPrep
were exported from Maestro. Ligands were docked 10 times with slow genetic algorithm and
with the heme-modified ChemScore as the scoring function [32].
The systems for the MD simulations were created with the Desmond system builder using
the SPC water model yielding an orthorhombic box with a buffer size of 10 Å between the pro-
tein and the box boundary. The system was neutralized with Na+ ions. The final systems con-
tained a total of close to 60,000 atoms including 7,360 atoms for the protein including the
heme group, 18 atoms for DTT, 13 Na+ ions and approximately 18,000 water molecules for the
neutral forms of DTT. MD simulations were performed with the Desmond program (version
3.6) [33] using the OPLS-2005 force field [30]. The default equilibration protocol was used for
equilibrating the systems. Subsequently, the systems were simulated for 100 ns.
Results and discussion
X-ray crystallography
The crystal structure of the M11 mutant of the heme domain of CYP BM3 in complex with
DTT was determined and refined at a resolution of 2.16 Å (Table 1). The overall structure is
similar to the previously published structure of the M11 mutant (PDB entry 5E9Z): it shows
four enzyme molecules in the asymmetric unit (S1 Fig, S1 and S2 Tables) [16] and the enzyme
is observed in the substrate-bound (SB) conformation [8]. The SB conformation of M11 is
compared to 1JPZ [34] and the superposition shows that the access channel is closed, as helices
F, G and H and the loops between them are tilted (Fig 2A). Helix I is observed with a small
kink as described for the SB conformation (Fig 2). The conformations of chain C and D are
difficult to describe because some loop areas were not observed, although chain D appears to
adopt a slightly different conformation for helix F and G (Fig 2A).
DTT was added to the protein sample and to the reservoir solution before crystallizing the
M11 protein ligand complex. As found by Capoferri et al. [16], a DTT molecule is observed to
form a disulfide bridge between the Cys198 residues in chain A and B. Due to the unobserved
loop regions in chain C and D, this disulfide bridge is not found here. The DTT molecule
observed between chain A and B is refined with full occupancy, indicating full presence of the
disulfide bridge (S2 Fig). This may be a reason for the observed crystal packing, which com-
prises four M11 protein chains in the asymmetric unit.
In contrast to our previous crystallographic study [16], the observed electron densities in
the active sites close to the heme iron in all four chains in our current structure reveal the pres-
ence of DTT (Fig 2B, and S3 Fig). One of the sulfur atoms of DTT is observed close to the
heme iron. The Fe–SDTT distance is 2.32 Å in the A chain, which suggests ligand coordination
Structure of P450 BM3 mutant M11 bound to dithiothreitol
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as it is comparable to the interaction observed on the other side of the heme group, where the
Fe–SCys400 distance is 2.31 Å (Fig 2B). Note that the Fe–S distances (Fe–SDTT and Fe–SCys400)
used for refinement are based on the considerations described in the next subsection (Related
crystal structures) and a similar value for these two Fe-S distances is in line with our results
described in the Spectroscopic studies subsection.
Direct hydrogen bonding interactions between the DTT molecules and active site residues
or water molecules are not observed. In all four chains DTT has been modelled in a similar
conformation and orientation but the electron density is not sufficiently well-defined to iden-
tify the precise positions of all DTT atoms, which may indicate ligand flexibility. Several differ-
ent orientations or conformations of DTT can be modelled into the density map, with a sulfur
atom coordinating Fe in all of them. Since DTT was added as a racemic mixture, both the R,R-
and S,S-enantiomers have been modelled into the electron density. It cannot unambiguously
be identified which enantiomer is, or if a mixture of both are coordinating Fe. Only the R,R-
enantiomer is included in the final structure.
Related crystal structures
The Protein Data Bank [35] contains more than 70 CYP BM3 structures (cf. S3 Table). The
majority of these structures were determined to study the effect of single or multiple amino
acid mutations on the ability of the enzyme to perform various organic reactions. DTT is only
observed for the structure 5E9Z and our structure.
In the Protein Data Bank, we identified three different types of protein structures with a
mercapto-containing compound coordinating to the Fe atom in a porphyrin ring. In the first
group hydrogen sulfide or a low-molecular weight mercaptane, including DTT and DTT ste-
reoisomers, occupies the axial position as the sixth ligand coordinating the Fe atom, but in all
these cases, the other axial ligand is a histidine. The shortest Fe-S distance (2.18 Å) is observed
Fig 2. Final structure of the heme domain of the CYP BM3 M11 mutant in complex with DTT. (A) Chains B, C, and D are superposed on chain A. For
comparison PDB entry 1JPZ (chain A) with the SB conformation [34] is superposed on chain A. Only helices F, G and H with the loops between them are
shown as cartoon, together with helix I and Cys400. DTT and the heme moiety from all four chains are shown as sticks and colored white. The A chain is
colored green, B cyan, C salmon, D slate and 1JPZ in grey. (B) Zoom on helix I and Cys400 of chain A together with its heme group and DTT, with 2Fo−Fc
omit electron density map contoured at 1σ and carved at 2.0 A˚ around DTT.
https://doi.org/10.1371/journal.pone.0217292.g002
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for DTT binding to rat heme oxygenase (PDB entry 3I9T, Fig 3) [36]. Slightly longer Fe-S dis-
tances (2.2–2.3 Å) are observed for the other members of this first group (PDB entries 3I8R,
3I9U, 4HPA, 4HPB, 4HPC, 4HPD and 4V2K, S4 and S5 Figs) [36–38]. A second group com-
prises two structures (PDB entries 2EVP and 2PBJ) with penta-coordinated Fe atoms, which
show longer Fe-S distances of 2.41 and 2.65 Å, respectively (S5 Fig) [39, 40]. Finally, the third
group contains only one member, i.e., the Azotobacter vinelandii bacterioferritin structure
(PDB entry 2FKZ), where the porphyrin ring is sandwiched between two methionine residues
(S5 Fig) [41].
Three-dimensional structures of heme-complexes are not only available from the Protein
Data Bank (PDB). The Cambridge Structural Database (CSD) [42] contains several porphyrin
structures, although a limited number of these have a sulfur atom coordinating the iron atom
and only a few are relevant in our context. The advantage of the CSD structures relative to the
PDB structures is generally that the hydrogens are unambiguously determined.
The DIDCEY structure from CSD is especially interesting because the iron is hexa-coordi-
nated with two 2,3,5,6-tetrafluorobenzenethiolate ions occupying the axial positions. The Fe-S
distances are 2.31 Å and the porphyrin ring is completely planar (Fig 4) [43].
Four additional sulfur-iron coordinating heme complexes are presented in S6 Fig. These
include the CORNAY structure, which has a single hydrosulfide ion (HS-) coordinating the
low-spin iron(III) as the axial ligand with a Fe-S distance of 2.30 Å [44]. In the WAHLAU and
WAHLEY structures a hydrosulfide ion (HS-) is coordinating the high-spin iron(II) with a Fe-
S distance of 2.4 Å [45]. In JELMIW an ethanethiolate ion is taking up the axial position
Fig 3. 3I9T crystal structure. Heme group, His25 and DTT from the 3D structure of DTT binding to rat heme oxygenase (PDB entry 3I9T
[36]).
https://doi.org/10.1371/journal.pone.0217292.g003
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relative to the high-spin iron(II) atom with a Fe-S distance of 2.32 Å [46]. These four structures
are characterized with non-planar porphyrin rings (cf. S6 Fig).
The above CSD structures confirm that the mercapto-compounds bind in their anionic
form to the Fe atom in the porphyrin ring. Finally, the analysis of the observed Fe-S distances
observed in PDB and CSD has been used as guide during structure refinement.
Spectroscopic studies
Binding of sulfur-containing compounds to heme proteins has been studied by spectroscopic
methods by several researchers [47–49]. Based on UV/Vis spectroscopy, magnetic circular
dichroism and electron paramagnetic resonance spectroscopy, Sono et al. showed some time
ago that binding of thiols and thiolates to ferric Cytochrome P450cam is competitive with sub-
strate binding and that thiolates typically bind three order of magnitudes better than thiols
[48]. From the observed Soret maxima of the P450cam-thiol(ate) complexes they also con-
cluded that the sixth sulfur ligand was binding as a mixture of the thiol (6c-HSR) and thiolate
(6c-SR), and that the equilibrium between the thiol-thiolate complexes was pH dependent (Fig
5). Finally, they showed that the pKa values of the thiols might be lowered with up to four units
by ligation to P450cam [48].
In a recent publication, Sono et al. extended their original work to ferrous heme-containing
proteins [49]. By UV/Vis spectroscopy they showed that ethanethiol binds to the heme in its
anionic thiolate form. Gorren et al. [47] studied the binding of DTT and other sulfur-contain-
ing ligands, to neuronal nitric oxide synthase (nNOS). They found that DTT binds to the
Fig 4. DIDCEY crystal structure. 3D representation of the DIDCEY structure containing a porphyrin ring with two 2,3,5,6-
tetrafluorobenzenethiolate ions coordinated to the Fe atom [43].
https://doi.org/10.1371/journal.pone.0217292.g004
Structure of P450 BM3 mutant M11 bound to dithiothreitol
PLOS ONE | https://doi.org/10.1371/journal.pone.0217292 May 24, 2019 8 / 15
heme group and forms a bisthiolate complex with an apparent dissociation constant KD = 0.16
nM. DTT was also shown to be a L-arginine competitive inhibitor with Ki = 11 mM.
Here we performed UV/Vis spectrophotometric titration studies of CYP BM3 M11 with
DTT to study its type of binding (Fig 6). The obtained absorbance difference spectra show
maxima at approximately 380 and 463 nm, and a minimum close to 417 nm (i.e., at 420 nm,
Fig 6A). From a comparison with the Soret maxima reported by Sono et al. in their studies on
Fig 5. Thiol-heme binding. The equilibria between binding of thiols, thiolates and other ligands to heme proteins as suggested in reference [48]. 5c and 6c
refer to the iron being five- and six-coordinated, respectively. Soret maxima are from reference [48] as well.
https://doi.org/10.1371/journal.pone.0217292.g005
Fig 6. DTT to M11 binding. (A) UV/Vis absorbance difference spectra for binding of DTT to CYP BM3 mutant M11 at different DTT concentrations between
0 and 96 μM (increasing in steps of 6 μM, as indicated by the different lines with the dark-brown line corresponding to 6 μM and the lightblue line to 96 μM).
(B) Differences in absorbance between 380 and 420 nm at the different DTT concentrations as used for fitting apparent values for dissociation constant KD.
Averages are given for triplicated experiments, together with associated error bars.
https://doi.org/10.1371/journal.pone.0217292.g006
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binding of sulfur-containing compounds to P450cam [48], this confirms the possibility of
heme iron coordination by DTT as observed in our crystal structure and it indicates that DTT
coordinates in its anionic form to Fe (cf. Fig 5). The apparent KD value was fitted from Fig 6B,
and determined to be 56.8 ± 1.3 μM.
Molecular dynamics simulations
The DTT molecule, both in the neutral form (both as R,R- and S,S-isomer) and as the monova-
lent anion (only R,R-isomer), was docked into the active site of the CYP BM3 M11 mutant
Fig 7. Fe-S distances from MD. Time series of Fe-S distances from MD simulations of CYP BM3 mutant M11 in complex with the
neutral form (A and B) and monovalent anion (C) of the (R,R)-isomer of DTT.
https://doi.org/10.1371/journal.pone.0217292.g007
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using the GOLD docking program and the ChemScore scoring function developed specifically
for docking to CYPs [31,32]. For the neutral forms of DTT, we obtained several binding poses,
and the best scoring poses were positioned with one of the DTT sulfur atom in the vicinity of
the Fe atom (2.4–2.6 Å). Four poses were selected as input for 100 ns of MD simulations. Only
the results of the MD simulation for the pose with the shortest Fe-S distance will be discussed
here. During the MD simulation the Fe-S distances d1 and d2 varied considerably
(d1 = 8.1 ± 2.0 Å and d2 = 8.7 ± 2.5 Å, cf. Fig 7) and none of the sulfur atoms got closer to Fe
than 5 Å after equilibration. Actually, it appeared as the neutral DTT molecule slowly drifted
away from the heme group in all simulations.
In contrast, docking of the mono-anion form of R,R-isomer of DTT only yielded a single
pose positioned with the negatively charged sulfur atom coordinating directly to the Fe atom
(2.61 atom vicinity teractionsgroup, probabthe heme group. dons Å). MD simulations with
this pose as starting conformation revealed that the DTT mono-anion maintained its contact
with Fe (d1 = 2.74 ± 0.03 Å and d2 = 8.56 ± 0.47 Å) (Fig 7).
Thus, the MD simulations confirm close contacts between the Fe and the negatively
charged sulfur, and that there are no specific interactions between the remaining of the DTT
molecule and the protein residues.
Conclusions
We presented a crystal structure of CYP BM3 mutant M11 in complex with a ligand. Over the
last 10 years, this “humanized” CYP BM3 variant has shown potential as biocatalyst and as
template to engineer mutants that selectively metabolize drugs and drug-like compounds. Our
crystal structure represents, to our knowledge, the first structure of the CYP BM3 mutant M11
with a ligand, DTT, bound directly to the heme iron. Our crystal structure indicates that bind-
ing of a DTT ligand to M11 does not significantly alter the protein conformation, which
underlines the use of the structure of this promiscuous enzyme for modeling purposes. Our
work also shows that DTT coordinates with the heme iron, with a Fe-S distance of 2.3 Å.
Absorbance difference spectra obtained in UV/Vis spectroscopic titration of M11 with DTT
demonstrate coordination by the ligand in its anionic form. Docking and molecular dynamics
simulations also suggest that the monovalent DTT anion can adopt a heme iron-coordinating
binding pose, in which no specific interactions between DTT and the active-site residues are
observed. This finding is in line with our interpretation from the obtained electron density
map that DTT remains relatively flexible in its observed active-site bound conformation.
Supporting information
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and 5E9Z in pale cyan. Root-mean-square deviations are presented in S1 Table. (A) Chain A
from both structures. (B) Chain B from both structures. (C) Chain C from both structures. (D)
Chain D from both structures.
(PDF)
S2 Fig. The DTT molecule bridging the A and B chain in the CYP BM3 M11 structure.
Potential H-bonds between DTT and Arg190 and three water molecules are shown as dashed
black lines. Part of the protein is shown as cartoon (chain A in green and chain B in cyan),
DTT and Arg190 in sticks.
(PDF)
Structure of P450 BM3 mutant M11 bound to dithiothreitol
PLOS ONE | https://doi.org/10.1371/journal.pone.0217292 May 24, 2019 11 / 15
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S1 Table. The present structure of CYP BM3 M11 in complex with DTT, compared to the
structure without ligand (5E9Z). Root-mean-square deviations (RMSDs, in Å) between
chains. Alignment is performed and RMSDs are calculated for Cα atoms using Pymol (Version
2.0.6, Schrodinger). Structures are shown in S1 Fig.
(PDF)
S2 Table. Root-mean-square deviations (RMSDs, in Å) between the four protein chains in
the asymmetric unit of the present CYP BM3 M11 structure. Chain A was used for compari-
son. Alignment is performed and RMSDs are calculated for Cα atoms using Pymol (Version
2.0.6, Schrodinger).
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